Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Sun Yat-sen University

Status and phase

Unknown

Phase 2

Conditions

Ovarian Cancer

Treatments

Drug: Pegylated liposomal doxorubicin

Drug: Fludarabine and Pegylated liposomal doxorubicin

Study type

Interventional

Funder types

Other

Identifiers

NCT03335241

308-2016-03-01

Details and patient eligibility

About

The purpose of the study is to evaluate the efficacy and toxicity of fludarabine with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum resistant or refractory ovarian cancer.

Full description

Ovarian cancer is the leading cause of death for patients with gynecologic malignancies. Approximately 75% of patients are diagnosed at an advanced stage will eventually experience disease recurrence. The overall response rates of second-line chemotherapy for recurrent ovarian cancer are only 20-27%. The 5-year overall survival rates are less than 20%. Therefore, it is important to seek alternative agent that can improve the outcome. Fludarabine is a purine nucleoside analog prodrug that upon phosphorylation is toxic to dividing and quiescent lymphocytes and monocytes, exerting its effects through DNA synthesis interference and apoptosis. The preclinical studies suggest fludarabine may be effective in other cancers such as ovarian cancer. Therefore, the purpose of this study is to test the efficacy and safety of the study drug fludarabine combined with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum resistant or refractory ovarian cancer.

Enrollment

140 estimated patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the ovary.
Platinum resistant or refractory ovarian cancer
At least treated with one line of platinum-based chemotherapy
Female, age ≥18 years and ≤70 years, signed informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 version
Patients must have a life expectancy of at least 3 months.
Patients must have adequate organ function as defined by the following criteria:
- White blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.0 x 10^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 80 x 10^9/L
- Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2.5 x ULN
- Serum creatinine ≤ 1 x ULN
Symptomatic central nervous system (CNS) metastasis

Exclusion Critera:

Has known allergies to any of the excipients.
Prior treatment with adriamycin or other anthracycline at cumulative doses greater than 550 mg/m2 after 6 cycles of pegylated liposomal doxorubicin
LVEF (left ventricular ejection fraction) <50%
Had disease recurrence/progression within 6 months after the administration of doxorubicin chemotherapy
History of myocardial infarction, or unstable angina, or New York Heart Association (NYHA) Grade III-IV within 6 months prior to Day 1.
Known significant chronic liver disease, such as cirrhosis or active hepatitis
Uncontrollable active infection